• First-in-human trial demonstrates that intravenous hDPSCs (NestaCell®) are safe and well-tolerated in Huntington’s disease patients over five years.
• No serious adverse events were directly attributed to the stem cell product; the only serious event (lung cancer) was unrelated to the cells, with no evidence of engraftment.
• Treatment-related adverse events were limited to transient hair pigmentation changes, indicating a favorable safety profile.
• The study supports further clinical development of hDPSC therapy for neurodegenerative disorders, with preliminary evidence of potential efficacy.